Immune Design Corp (IMDZ.OQ)
IMDZ.OQ on NASDAQ Stock Exchange Global Market
3.42USD
13 Aug 2018
3.42USD
13 Aug 2018
Change (% chg)
$-0.08 (-2.14%)
$-0.08 (-2.14%)
Prev Close
$3.50
$3.50
Open
$3.55
$3.55
Day's High
$3.55
$3.55
Day's Low
$3.15
$3.15
Volume
36,489
36,489
Avg. Vol
38,691
38,691
52-wk High
$11.20
$11.20
52-wk Low
$2.80
$2.80
About
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to... (more)
Overall
| Beta: | -- |
| Market Cap(Mil.): | $269.01 |
| Shares Outstanding(Mil.): | 25.62 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| IMDZ.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 85.68 | 32.76 |
| EPS (TTM): | -2.20 | -- | -- |
| ROI: | -66.38 | 1.78 | 14.61 |
| ROE: | -66.44 | 3.28 | 16.33 |
BRIEF-Immune Design Q1 Loss Per Share $0.28
* IMMUNE DESIGN REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
BRIEF-Immune Design Reports Q4 Loss Per Share $0.29
* IMMUNE DESIGN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
BRIEF-Immune Design Reports Data Update For Lead Immunotherapy Programs
* IMMUNE DESIGN REPORTS DATA UPDATE FOR LEAD IMMUNOTHERAPY PROGRAMS: IMPROVEMENT IN SURVIVAL FOR CMB305 MONOTHERAPY IN SARCOMA AND INCREASED OBJECTIVE RESPONSES FOR G100/PEMBROLIZUMAB COMBINATION IN FOLLICULAR LYMPHOMA
BRIEF-Immune Design To Report Q4 And Year End 2017 Financial Results And Provide Corporate Update
* IMMUNE DESIGN TO REPORT FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:
Estimates